A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers

Conclusion: We proved superiority of new proposed model using immunohistochemical markers over standard clinical practice and that new proposed model increases accuracy of prognosis prediction. We propose wider implementation and validation of the proposed model. Introduction Endometrial carcinoma (EC) is one of the most common female cancers. It predominantly has a favorable prognosis, due to the early onset of signs and symptoms such as postmenopausal bleeding or spotting, which lead to early-stage diagnosis in most patients and five-year overall survival rates of up to 85% (1). However, 20% of those EC patients who are estimated to be at low risk of recurrence will nevertheless recur while up to 50% of those designated “high-risk” will not (2, 3). It is clear the prognostic markers currently used (FIGO stage, tumor subtype, and histological grade) are far from optimal in terms of preoperative stratification of patients into low- or high-risk groups regarding surgical planning and adjuvant treatment. One of the currently used prognostic markers is FIGO stage. This is obligatory and determined by transvaginal ultrasound of the pelvis (US). Computed tomography (CT) of the chest and abdomen is an imaging method of choice and is routinely used to exclude retroperitoneal lymphadenopathy and metastases in parenchymal organs. The other prognostic markers, histotype, and grade of tumor differentiation, are assessed from a biopsy obtained either by dilatatio...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research